PDA initiative connecting drug manufacturers, glass suppliers to make manufacturing great
First initiative is to eliminate visible particles from parenteral products,
The Parenteral Drug Association (PDA) has announced a significant initiative to bring together executives, including CEOs and executive vice presidents, from biologic and pharmaceutical manufacturers with glass container and elastomeric closure suppliers to prepare industry for the complex products and manufacturing processes of the future. They aspire to achieve this through collective and collaborative continuous improvement projects to take today's world-class injectable medicine manufacturing to the next level.
Their first initiative is to eliminate visible particles from parenteral products. Since December, a PDA task force, consisting of multidisciplinary members from biologic and pharmaceutical manufacturers and suppliers of glass container and elastomeric closures with more than 1,000 years of experience combined, has been meeting with a focus on the entire supply chain from raw materials to finished product. This initiative represents an audacious goal, and will only succeed with all affected parties working collaboratively toward the objective of eliminating visible particles.
PDA is also proud to announce a memorandum of understanding with the BioPhorum Operations Group who has worked with a team of professionals to improve the performance of rubber closures for parenteral products. The memorandum of understanding expands the collaboration and accelerates the development of best practices and standards, while striving to avoid the development of conflicting approaches.
Patients will be the key beneficiary from this effort to ensure quality medicines are delivered in a robust and reliable supply chain. The goals of the initiative epitomizes PDA's mission to advance pharmaceutical / biopharmaceutical manufacturing science and regulation so its members can better serve patients.
The initiative was made possible by PDA Chairman of the Board, Martin VanTrieste, who worked diligently to persuade over 40 executives representing over 30 companies to come to Bethesda, Maryland to join forces and work together to serve patients. These executives committed the necessary resources to staff the initiative with subject-matter experts consisting of manufacturing professionals, supply chain professionals, quality professionals, engineers, scientist and physicians.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance